Effects of Sacubitril/Valsartan combined with Metoprolol tartrate in treatment of patients with hypertension and heart failure
Objective:To observe effects of Sacubitril/Valsartan combined with Metoprolol tartrate in treatment of patients with hypertension and heart failure.Methods:A prospective study was conducted on 80 patients with hypertension and heart failure admitted to the hospital from January 2021 to January 2023.According to the random number table method,they were divided into control group and observation group,40 cases in each group.The control group was treated with Metoprolol tartrate tablets,while the observation group was treated with Sacubitril/Valsartan sodium tablets on the basis of that of the control group.The clinical efficacy,the blood pressure,the cardiac function indexes[left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),cardiac output(CO)],the myocardial injury markers[N-terminal pro-brain natriuretic peptide(NT-proBNP),troponin I(cTnI),brain natriuretic peptide(BNP)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group was 95.00%(38/40),which was higher than 77.50%(31/40)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of diastolic blood pressure and systolic blood pressure in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of LVESD and LVEDD in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;the levels of LVEF and CO in the two groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;and the differences were statistically significant(P<0.05).The levels of NT-proBNP,cTnI and BNP in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Sacubitril/Valsartan combined with Metoprolol tartrate in the treatment of the patients with hypertension and heart failure can improve the clinical efficacy,improve the levels of cardiac function indexes,and reduce the levels of blood pressure and myocardial injury markers.Moreover,it is superior to simple Metoprolol tartrate treatment.
NETL
NSTL
万方数据
